EXPRESSF+

Cell lines for use in the production of recombinant proteins for medical and clinical use and cells for medical or clinical use, including an insect line, a baculovirus-suspectible insect cell line, and a spodoptera frugiperda cell line having one or more of the following characteristics - cells which are genetically and morphologically distinct from the parent of Sf9 cells, cells which replicate in serum-free medium, cells which grow as a suspension of single cells without significant clumping, cells which grow exponentially with a cell doubling time of 18 to 24 hours, cells which can be passed continuously for at least 6 months while maintaining a high level of viability (>98%), cells which are highly permissive to infection with californica npv baculoviruses resulting in high-titered virus stocks, cells which are useful for the production of recombinant DNA gene cell products following infection with baculovirus vectors, cells which are useful for the production and plaque-isolation of genetically engineered baculovirus cells which meet the general identity and safety requirements for cells set by government regulatory agencies, and cells which are suitable for the manufacture of biological pharmaceutical products following cGMP standards

Cell lines for use in the production of recombinant proteins for scientific, laboratory and medical research and cells for research of a scientific, laboratory or medical nature, including an insect line, a baculovirus-suspectible insect cell line, and a spodoptera frugiperda cell line having one or more of the following characteristics - cells which are genetically and morphologically distinct from the parent Sf9 cells, cells which replicate in serum-free medium, cells which grow as a suspension of single cells without significant clumping, cells which grow exponentially with a cell doubling time of 18 to 24 hours, cells which can be passed continuously for at least 6 months while maintaining a high level of viability (>98%), cells which are highly permissive to infection with californica npv baculoviruses resulting in high-titered virus stocks, cells which are useful for the production of recombinant DNA gene cell products following infection with baculovirus vectors, cells which are useful for the production and plaque-isolation of genetically engineered baculovirus cells which meet the general identity and safety requirements for cells set by government regulatory agencies, and cells which are suitable for the manufacture of biological pharmaceutical products following cGMP standards